# Cannabichromevarin **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/cannabichromevarin **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-03-29 **Evidence Score:** 4 / 10 **Category:** Compound **Also Known As:** CBCV, Cannabichromevarinic acid precursor, Propyl cannabichromene, 3-carbon cannabichromene, CBC propyl variant ## Overview Cannabichromevarin (CBCV) is a minor cannabinoid that acts as a TRPA1 channel activator and CB2 receptor modulator. Preliminary research indicates potential anti-tumor and [anti-inflammatory](/ingredients/condition/inflammation) effects through cannabinoid receptor pathways. ## Health Benefits • Anti-tumor potential: In vitro studies show cytotoxic effects against breast and colon cancer cell lines (evidence: preliminary cell culture only) • [Anti-inflammatory](/ingredients/condition/inflammation) properties: Preliminary in vitro research indicates potential anti-inflammatory effects (evidence: cell-based studies only) • Antibacterial activity: Cell-based studies suggest effectiveness against certain bacterial strains including drug-resistant organisms (evidence: in vitro only) • Antioxidant neuroprotection: In vitro evidence indicates potential [neuroprotective effect](/ingredients/condition/cognitive)s through [oxidative stress](/ingredients/condition/antioxidant) reduction (evidence: cell culture only) • Pain management potential: Preliminary in vitro research suggests analgesic properties (evidence: cell-based studies only) ## Mechanism of Action Cannabichromevarin primarily activates TRPA1 (transient receptor potential ankyrin 1) channels and modulates CB2 cannabinoid receptors. The compound appears to influence inflammatory cascades by inhibiting [pro-inflammatory cytokine](/ingredients/condition/inflammation) production, particularly TNF-α and IL-6. CBCV may also interact with vanilloid receptors (TRPV1) to produce therapeutic effects. ## Clinical Summary Current evidence for cannabichromevarin is limited to preliminary in vitro studies using isolated cell cultures. Cell-based research shows cytotoxic effects against MCF-7 breast cancer and HT-29 colon cancer cell lines, though specific IC50 values have not been established. [Anti-inflammatory](/ingredients/condition/inflammation) studies demonstrate reduced inflammatory marker expression in activated immune cells. No human clinical trials or animal studies have been published to date, making therapeutic claims premature. ## Nutritional Profile Cannabichromevarin (CBCV) is a non-psychoactive phytocannabinoid and homolog of cannabichromene (CBC), classified as a trace compound found in Cannabis sativa. It is not a nutritional ingredient and contains no meaningful macronutrients (carbohydrates, proteins, or fats), micronutrients, vitamins, or dietary fiber in any biologically relevant quantity. CBCV is a propyl-chain analog of CBC, differing by the substitution of a pentyl side chain with a propyl side chain, resulting in a molecular formula of C19H26O2 and a molecular weight of approximately 286.41 g/mol. As a terpenophenolic compound, its bioactive concentration in raw cannabis plant material is typically below 1% by dry weight, often in the range of trace to 0.1–0.5% in select cultivars. It belongs to the cannabinoid class of bioactive compounds, interacting primarily with transient receptor potential (TRP) channels (notably TRPA1 and TRPV1) rather than CB1 or CB2 receptors with high affinity. Bioavailability data specific to CBCV is not yet established in human studies; however, by structural analogy to other propyl-chain cannabinoids (e.g., THCV, CBDV), oral bioavailability is expected to be low due to first-pass [metabolism](/ingredients/condition/weight-management) and high lipophilicity (estimated logP ~5–6), with improved absorption in lipid-rich delivery matrices. No caloric value, mineral content, or vitamin contribution is documented. ## Dosage & Preparation No clinically established dosage ranges exist for CBCV in humans as no human clinical trials have been conducted. There are no evidence-based dosing recommendations for any formulation (extract, powder, or standardized preparation). Consult a healthcare provider before starting any new supplement. ## Safety & Drug Interactions No safety data exists for cannabichromevarin in humans due to lack of clinical trials. As a cannabinoid compound, CBCV may theoretically interact with medications metabolized by CYP3A4 enzymes, including certain blood thinners and seizure medications. Potential side effects are unknown but may include cannabinoid-related effects such as drowsiness or altered [blood pressure](/ingredients/condition/heart-health). Pregnant and breastfeeding women should avoid use due to insufficient safety data. ## Scientific Research No human clinical trials, randomized controlled trials, or meta-analyses of CBCV have been published in peer-reviewed literature. All current evidence consists entirely of in vitro (cell culture) and preclinical animal studies, with no PubMed PMIDs available for human trials because none exist. ## Historical & Cultural Context CBCV has no documented traditional medical use as it is a minor cannabinoid present only in trace amounts and was not specifically isolated or utilized in traditional medicine systems. Its study is entirely a product of modern phytochemical research post-2000s, unlike cannabis itself which has extensive traditional use. ## Synergistic Combinations CBD, CBC, CBG, Full-spectrum hemp extract, Terpenes ## Frequently Asked Questions ### What is cannabichromevarin and how is it different from CBD? Cannabichromevarin (CBCV) is a minor cannabinoid with a propyl side chain, making it structurally distinct from CBD. Unlike CBD's broad receptor activity, CBCV primarily targets TRPA1 channels and CB2 receptors with different binding affinities. ### Is cannabichromevarin legal and available in supplements? CBCV's legal status varies by jurisdiction and depends on its source and THC content. Currently, CBCV is not commercially available in supplements due to extraction difficulties and lack of safety data from human studies. ### What cancers has cannabichromevarin been studied for? Laboratory studies have tested CBCV against breast cancer (MCF-7) and colon cancer (HT-29) cell lines, showing cytotoxic effects. However, these are only preliminary cell culture studies and do not indicate effectiveness in actual cancer treatment. ### How much cannabichromevarin should I take for health benefits? No safe or effective dosage has been established for CBCV since human studies have not been conducted. Current research is limited to cell culture experiments using various concentrations for laboratory testing only. ### Does cannabichromevarin show up on drug tests? CBCV itself is unlikely to trigger standard drug tests that screen for THC metabolites. However, cannabis-derived CBCV products may contain trace THC amounts that could potentially cause positive results depending on test sensitivity. ### What does the current research evidence show about cannabichromevarin's effectiveness? Current evidence for cannabichromevarin is limited to preliminary in vitro (cell culture) studies, which have not yet progressed to human clinical trials. While cell-based research suggests potential anti-tumor, anti-inflammatory, and antibacterial properties, these findings cannot be reliably extrapolated to human health benefits without robust clinical evidence. The ingredient remains in early-stage investigation and should not be considered proven for any therapeutic use in humans. ### Is cannabichromevarin safe to use alongside common medications? There is insufficient research on cannabichromevarin's interactions with medications to provide definitive safety guidance. As with other cannabinoid compounds, there is potential for interactions with drugs metabolized by cytochrome P450 enzymes, but this has not been specifically studied for cannabichromevarin. Individuals taking prescription medications should consult a healthcare provider before using cannabichromevarin supplements. ### Who might benefit most from cannabichromevarin supplementation based on current research? Based on available evidence, no specific population can be identified as benefiting from cannabichromevarin supplementation, as clinical trials in humans have not been conducted. The preliminary research suggests potential interest for those exploring emerging cannabinoid research, but these findings are too early-stage to recommend supplementation for any particular health condition or demographic group. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*